Pfizer's innovative business should grow faster after it divests its off-patent division Upjohn in 2020 to create Viatris and ...

Pfizer is making more changes to its marketing partnerships. According to a report from Campaign US, 2 Pfizer will now be working with Publicis for its global creative duties. IPG will still hold ...

Pfizer Inc. (NYSE:PFE) is navigating a period of strategic upheaval and legal scrutiny as it ends its clinical collaboration ...

Pfizer Global Supply features 36 manufacturing sites ... and we have hundreds of partnerships with manufacturing organizations and suppliers." Scale allows Pfizer to minimize supply chain risk ...

Investing.com -- Sangamo's shares have seen a decrease of around 27% in response to Pfizer (NYSE: PFE)'s decision to end the global collaboration and license agreement between the two companies.

Pfizer Inc. has agreed to buy Global Blood Therapeutics Inc. for $5.4 billion, in a deal that would give the big drugmaker a foothold in the treatment of sickle-cell disease. Pfizer said Monday it ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Seongnam: SK bioscience, a global vaccine and biotech company, has announced that the Supreme Court of Korea has ruled in its favor in a patent infringement lawsuit filed by large ...

These include the partnership with Haya Karima in ... change patients' lives in the region and beyond". Pfizer's recent acquisition of global biotech company Seagen marked the beginning of a ...

These include the partnership with Haya Karima in ... patients’ lives in the region and beyond”. Pfizer’s recent acquisition of global biotech company Seagen marked the beginning of a ...

This development comes at a time when global healthcare companies are intensifying their focus on innovation in key Asian markets. The opening of the R&D centre is expected to bolster Pfizer’s ...